Xeris Biopharma Holdings Analyst Ratings
Xeris Biopharma Holdings Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 132.56% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/10/2023 | 132.56% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/09/2023 | 132.56% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 01/27/2023 | 93.8% | SVB Leerink | $6 → $5 | Maintains | Outperform |
| 10/21/2022 | 55.04% | Jefferies | → $4 | Assumes | → Buy |
| 04/28/2022 | 151.94% | Craig-Hallum | → $6.5 | Initiates Coverage On | → Buy |
| 03/16/2022 | 132.56% | Mizuho | $8 → $6 | Maintains | Buy |
| 02/16/2022 | 132.56% | SVB Leerink | $8 → $6 | Maintains | Outperform |
| 12/31/2021 | 210.08% | SVB Leerink | $6 → $8 | Maintains | Outperform |
| 12/31/2021 | 109.3% | HC Wainwright & Co. | $4.25 → $5.4 | Maintains | Buy |
| 11/17/2021 | 132.56% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
| 10/29/2021 | 55.04% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 04/23/2020 | 442.64% | Mizuho | $18 → $14 | Maintains | Buy |
| 02/20/2020 | 597.67% | Mizuho | $22 → $18 | Maintains | Buy |
| 02/18/2020 | 365.12% | Piper Sandler | → $12 | Initiates Coverage On | → Overweight |
| 09/11/2019 | 752.71% | Mizuho | $27 → $22 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/09/2023 | 132.56% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 2023年05月10日 | 132.56% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 03/09/2023 | 132.56% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 2023年1月27日 | 93.8% | SVB Leerink | $6→$5 | 維護 | 跑贏大盤 |
| 2022年10月21日 | 55.04% | 傑富瑞 | →$4 | 假設 | →購買 |
| 04/28/2022 | 151.94% | 克雷格-哈勒姆 | →$6.5 | 開始承保 | →購買 |
| 03/16/2022 | 132.56% | 瑞穗 | $8→$6 | 維護 | 買 |
| 02/16/2022 | 132.56% | SVB Leerink | $8→$6 | 維護 | 跑贏大盤 |
| 2021年12月31日 | 210.08% | SVB Leerink | $6→$8 | 維護 | 跑贏大盤 |
| 2021年12月31日 | 109.3% | HC Wainwright公司 | $4.25→$5.4 | 維護 | 買 |
| 2021年11月17日 | 132.56% | SVB Leerink | →$6 | 開始承保 | →跑贏大盤 |
| 10/29/2021 | 55.04% | HC Wainwright公司 | →$4 | 開始承保 | →購買 |
| 04/23/2020 | 442.64% | 瑞穗 | $18→$14 | 維護 | 買 |
| 02/20/2020 | 597.67% | 瑞穗 | $22→$18 | 維護 | 買 |
| 02/18/2020 | 365.12% | 派珀·桑德勒 | →$12 | 開始承保 | →超重 |
| 2019/11/09 | 752.71% | 瑞穗 | $27→$22 | 維護 | 買 |
What is the target price for Xeris Biopharma Holdings (XERS)?
Xeris Biophma Holdings(XERS)的目標價是多少？
The latest price target for Xeris Biopharma Holdings (NASDAQ: XERS) was reported by HC Wainwright & Co. on August 9, 2023. The analyst firm set a price target for $6.00 expecting XERS to rise to within 12 months (a possible 132.56% upside). 5 analyst firms have reported ratings in the last year.
納斯達克控股公司(納斯達克代碼：XERS)的最新目標價是由HC Wainwright&Co.於2023年8月9日報道的。這家分析公司將目標價定為6美元，預計Xers將在12個月內上漲至(可能上漲132.56)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Xeris Biopharma Holdings (XERS)?
Xeris Biophma Holdings(XERS)的最新分析師評級是多少？
The latest analyst rating for Xeris Biopharma Holdings (NASDAQ: XERS) was provided by HC Wainwright & Co., and Xeris Biopharma Holdings reiterated their buy rating.
納斯達克(Sequoia Capital：XERS)的最新分析師評級由HC Wainwright&Co.提供，Xeris Biophma Holdings重申其買入評級。
When is the next analyst rating going to be posted or updated for Xeris Biopharma Holdings (XERS)?
Xeris Biophma Holdings(Xers)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xeris Biopharma Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xeris Biopharma Holdings was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查看公開的財務報表，與Xeris Biophma Holdings的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Xeris Biophma Holdings的上一次評級是在2023年8月9日提交的，所以你應該預計下一次評級將在2024年8月9日左右的某個時候公佈。
Is the Analyst Rating Xeris Biopharma Holdings (XERS) correct?
分析師對Xeris Biophma Holdings(XERS)的評級正確嗎？
While ratings are subjective and will change, the latest Xeris Biopharma Holdings (XERS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Xeris Biopharma Holdings (XERS) is trading at is $2.58, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Xeris Biophma Holdings(Xers)評級被重申，目標價在0.00美元至6.00美元之間。Xeris Biophma Holdings(Xers)目前的交易價格為2.58美元，在分析師的預測範圍內。